Redox cycling quinones display antibacterial activity against Helicobacter pylori. Is oxidative stress playing a role ?

pedro buc calderon 2 paris redox 2017This strategic question will be answered during Paris Redox World Congress by Pr Pedro Buc Calderon, Co-Editor in-Chief of the Journal of ISANH and co-chairman of the scientific committee, University of Leuven, Belgium.

According to Pr Buc Calderon: "Helicobacter pylori (H. pylori), [...] is associated with a number of human diseases, including gastritis, peptic ulceration, and gastric cancer. Due to its direct incidence in human cancer, H. pylori is now classified as belonging to the Group 1 carcinogen [...]. Therefore, infection by H. pylori represents a major health concern nowadays. Indeed, the risk of developing gastric cancer is increased 10 times in people infected by this bacteria.

Due to the current difficulties to eradicate H. pylori, the search for new drugs and alternative therapies has become a crucial issue [...]. (In this study), we report the design and the in vitro evaluation of 2/3-arylaminojuglones as potential inhibitors of the bacteria. The results obtained [...] reveals a bacterial growth inhibition [...]. The antibacterial activity of juglone derivatives is analyzed in terms of antioxidant ability and some molecular descriptors such as molar refractivity, hydrophobicity and redox potential."

If you are interested to know more about this study, don't hesitate to join the attendees of Paris Redox World Congress. More information: